CoChat

CSF Aβ1‐42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease

Lista, Simone, Garaci, Francesco G., Ewers, Michael, Teipel, Stefan, Zetterberg, Henrik, Blennow, Kaj, Hampel, Harald · 2014 · Alzheimer's & Dementia
Cited by 76

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

The development of validated, qualified, and standardized biomarkers for Alzheimer's disease (AD) that allow for an early presymptomatic diagnosis and discrimination (classification) from other types of dementia and neurodegenerative diseases is warranted to accelerate the successful development of novel disease‐modifying therapies. Here, we focus on the value of the 42‐residue‐long amyloid β isoform (Aβ1‐42) peptide in the cerebrospinal fluid as the core, feasible neurobiochemical marker for the amyloidogenic mechanisms in early‐onset familial and late‐onset sporadic AD. We discuss the role and use of Aβ1‐42 in combination with evolving neuroimaging biomarkers in AD detection and diagnosis. Multimodal neuroimaging techniques, directly providing structural‐functional‐metabolic aspects of brain pathophysiology, are supportive to predict and monitor the progression of the disease. Advances in multimodal neuroimaging provide new insights into brain organization and enable the detection of specific proteins and/or protein aggregates associated with AD. The combination of biomarkers from different methodologies is believed to be of incrementally added risk‐value to accurately identify asymptomatic and prodromal individuals who will likely progress to dementia and represent rational biomarker candidates for preventive and symptomatic pharmacological intervention trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2013.04.506

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 76

Metadata

Authors
Lista, S., Garaci, F. G., Ewers, M., Teipel, S., Zetterberg, H., Blennow, K., & Hampel, H.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2013-07-15
Volume
10
Issue
3
Pages
381-392
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2102954898
Cited by
76
References
31
FWCI
6.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CSF Aβ1‐42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.jalz.2013.04.506
The paper
Lista, S., Garaci, F. G., Ewers, M., Teipel, S., Zetterberg, H., Blennow, K., & Hampel, H. (2014). CSF Aβ1‐42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2013.04.506

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.